By contrast, lung adenocarcinomas (LUAD), colorectal adenocarcinomas (COAD), and breast carcinomas (BRCA) overexpressed FOLH1 at a fold change of less than two, and these cancers have previously shown relatively low uptake and tumor-to-background ratios [15,16]. This evidence concerns the gene FOLH1 and lung adenocarcinoma.